Envoy Therapeutics’ mission is to discover new drugs with superior efficacy and fewer side effects than existing treatments. The company’s bacTRAP® technology enables the identification of proteins in vivo that are produced by specific cell types without requiring the isolation of those cells. The technology is especially powerful in tissues of the brain, where many hundreds of cell types are intermingled. Because therapeutically modulating the activity of a specific cell type has until now been prevented by the inability to determine which proteins are uniquely expressed by that cell type, Envoy brings a new day in drug discovery.

Our co-founders include a Nobel Laureate and a Lasker Award recipient, as well as a CEO who obtained his MBA from HBS and has a track record in building science based organizations. Our Board of Directors includes national leaders such as Senator Bill Bradley, while our scientific advisors include experienced drug developers.

Our company is off to a great start. Upon closing our first financing in October 2009, receiving investments from two global pharmaceutical companies and a Silicon Valley/Boston venture capital firm, we began implementing our drug discovery platform in our Jupiter, Florida laboratories. In only our first year, we formed significant research alliances with drug giant Merck as well as Takeda Pharmaceuticals, Japan's largest drug company. We've recruited a recognized medicinal chem

We’re passionate about creating and exploiting our completely new and unique drug discovery engine.